La cannabis in gravidanza

Lo studio è stato condotto su un gruppo di 103 donne, etnicamente differenti.
Circa il 15%  di queste aveva rilevabili concentrazioni di un qualche tipo di cannabinoide, indicando l’esposizione fetale alla cannabis.
La prole esposta alla sostanza, a differenza di quella non esposta all’azione della cannabis,  presentava:
– una massa grassa maggiore
– adiposità
– glicemia a digiuno.
Lo studio fornisce nuove prove che indicano una possibile associazione tra l’esposizione fetale alla cannabis e disturbi metabolici.

I risultati dovrebbero però essere  confermati da altri studi osservazionali.

Fonte

Brianna F Moore et al., Fetal Exposure to Cannabis and Childhood Metabolic Outcomes: The Healthy Start Study The Journal of Clinical Endocrinology & Metabolism, dgac101, Published: 31 March 2022.

Abstract
We leveraged a subsample of 103 mother-child pairs from Healthy Start, an ethnically diverse Colorado-based cohort.
Twelve cannabinoids/metabolites of cannabis (including Δ9-tetrahydrocannabinol and cannabidiol) were measured in maternal urine collected at ~27 weeks’ gestation.
Fetal exposure to cannabis was dichotomized as exposed (any cannabinoid > limit of detection [LOD]) and not exposed (all cannabinoids < LOD).

Approximately 15% of the women had detectable levels of any cannabinoid, indicating fetal exposure to cannabis.
Exposed offspring had:
– higher fat mass (1.0 kg; 95% CI, 0.3-1.7),
– fat-free mass (1.2 kg; 95% CI, 0.4-2.0),
– adiposity (2.6%; 95% CI, 0.1-5.2),
– and fasting glucose (5.6 mg/dL; 95% CI, 0.8-10.3) compared with nonexposed offspring

Conclusions
We provide novel evidence to suggest an association between fetal exposure to cannabis with increased adiposity and fasting glucose in childhood, a finding that should be validated in other cohorts.